Prothena GAAP EPS of -$2.34 misses by $0.55, revenue of $4.42M misses by $0.94M
Source: SeekingAlpha
2025-08-04 16:54:54 ET
More on Prothena
- Roche And Prothena: Why Moving On Makes Sense
- Prothena: Despite Phase 3 Trial Failure, Other Neurodegenerative Programs In Place
- Prothena Q2 2025 Earnings Preview
- Prothena to lay off 63% of workforce, revises full year guidance
- Seeking Alpha’s Quant Rating on Prothena
Read the full article on Seeking Alpha
For further details see:
Prothena GAAP EPS of -$2.34 misses by $0.55, revenue of $4.42M misses by $0.94M
Prothena Corporation plc
NASDAQ: PRTA
PRTA Trading
-1.3% G/L:
$9.11 Last:
210,412 Volume:
$9.40 Open:
PRTA Latest News
March 09, 2026 04:05:00 pm
Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy
PRTA Stock Data
$486,084,737
38,757,587
1.22%
55
N/A
Biotechnology & Life Sciences
Healthcare
IE
Dublin 2
